title: The Use of Anthracyclines for Therapy of CNS Tumors.
abstract: Despite being long lived, anthracyclines remain the "evergreen" drugs in clinical practice of oncology, showing a potent effect in inhibiting cell growth in many types of tumors, including brain neoplasms. Unfortunately, they suffer from a poor penetration into the brain when intravenously administered due to multidrug resistance mechanism, which hampers their delivery across the blood brain barrier. In this paper, we summarize the current literature on the role of anthracyclines in cancer therapy and highlight recent efforts on 1) development of tumor cell resistance to anthracyclines and 2) the new approaches to brain drug delivery across the blood brain barrier.
authors.forename: Martina
authors.initials: M
authors.lastname: da Ros
authors.forename: Anna Lisa
authors.initials: AL
authors.lastname: Iorio
authors.forename: Maurizio
authors.initials: M
authors.lastname: Lucchesi
authors.forename: Alessia
authors.initials: A
authors.lastname: Stival
authors.forename: Maurizio
authors.initials: M
authors.lastname: de Martino
authors.affiliation: Neuro-Oncology Unit, Department of Paediatric Medicine, Meyer Children's Hospital. Viale G. Pieraccini 24, 50139 Florence, Italy. iacopo.sardi@meyer.it.
authors.forename: Iacopo
authors.initials: I
authors.lastname: Sardi
mesh_terms: D000818:Animals; D018943:Anthracyclines / Q000008:administration & dosage*; D001812:Blood-Brain Barrier / Q000378:metabolism; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans
chemical_list: D018943:Anthracyclines
references.citation: J Liposome Res. 2002 Nov;12(4):301-9
references.pmid: 12519627
references.citation: Adv Drug Deliv Rev. 2013 Nov;65(13-14):1852-65
references.pmid: 24120954
references.citation: Drug Discov Today. 2012 Feb;17(3-4):160-6
references.pmid: 21983329
references.citation: Expert Opin Drug Deliv. 2009 Feb;6(2):165-76
references.pmid: 19239388
references.citation: ISRN Biochem. 2013 May 21;2013:238428
references.pmid: 25937958
references.citation: Eur J Pharm Biopharm. 2010 Feb;74(2):157-63
references.pmid: 19755158
references.citation: J Pharm Sci. 2014 Jul;103(7):2157-65
references.pmid: 24824141
references.citation: Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15205-10
references.pmid: 20696897
references.citation: J Neurooncol. 2002 Mar;57(1):27-36
references.pmid: 12125964
references.citation: Clin Cancer Res. 2004 Dec 1;10 (23 ):7896-902
references.pmid: 15585622
references.citation: PLoS One. 2011 May 06;6(5):e19121
references.pmid: 21573151
references.citation: Semin Oncol. 2004 Dec;31(6 Suppl 13):53-90
references.pmid: 15717738
references.citation: J Clin Invest. 1996 Jun 1;97(11):2517-24
references.pmid: 8647944
references.citation: Cancer Lett. 2014 Oct 28;353(2):242-7
references.pmid: 25079687
references.citation: Int J Nanomedicine. 2014 Jul 22;9:3465-79
references.pmid: 25092977
references.citation: Bioconjug Chem. 2008 Feb;19(2):525-31
references.pmid: 18163537
references.citation: J Control Release. 2012 Jul 20;161(2):264-73
references.pmid: 21872624
references.citation: J Pharm Sci. 2003 Jul;92(7):1343-55
references.pmid: 12820139
references.citation: Science. 1983 Sep 23;221(4617):1285-8
references.pmid: 6137059
references.citation: Acta Neurochir (Wien). 1990;104(1-2):13-6
references.pmid: 2386084
references.citation: Pharm Res. 2015 Jan;32(1):158-66
references.pmid: 25048636
references.citation: Nanomedicine. 2012 Feb;8(2):204-11
references.pmid: 21704592
references.citation: Int J Pharm. 2005 Jul 25;298(2):274-92
references.pmid: 15896933
references.citation: J Drug Target. 2006 Nov;14 (9):614-22
references.pmid: 17090397
references.citation: Cancer Chemother Pharmacol. 2011 Jun;67(6):1333-40
references.pmid: 20737150
references.citation: Part Fibre Toxicol. 2010 Mar 03;7:3
references.pmid: 20199661
references.citation: J Neurooncol. 2011 Sep;104(2):619-20
references.pmid: 21234643
references.citation: Tumori. 2008 Mar-Apr;94(2):271-7
references.pmid: 18564616
references.citation: Nanomedicine. 2014 Feb;10(2):381-91
references.pmid: 23916888
references.citation: Biochem Soc Trans. 2007 Feb;35(Pt 1):56-60
references.pmid: 17233601
references.citation: Adv Drug Deliv Rev. 2010 Feb 17;62(2):122-49
references.pmid: 19919846
references.citation: Drug Discov Today. 2014 Oct;19(10):1563-71
references.pmid: 24929222
references.citation: Pharmgenomics Pers Med. 2014 Feb 05;7:53-64
references.pmid: 24523596
references.citation: Future Oncol. 2013 Dec;9(12):1849-59
references.pmid: 24295415
references.citation: Pharm Res. 2012 Jul;29(7):1949-59
references.pmid: 22399388
references.citation: J Nanosci Nanotechnol. 2014 Jan;14(1):766-79
references.pmid: 24730296
references.citation: Biomaterials. 2011 Jun;32(18):4293-305
references.pmid: 21427009
references.citation: Eur J Pharm Biopharm. 2000 Jul;50(1):61-81
references.pmid: 10840193
references.citation: Curr Med Chem. 2006;13(5):477-523
references.pmid: 16515518
references.citation: Epilepsia. 2007;48 Suppl 1:8-13
references.pmid: 17316407
references.citation: Clin Pharmacokinet. 2003;42(5):419-36
references.pmid: 12739982
references.citation: Clin Transl Oncol. 2012 Feb;14(2):83-93
references.pmid: 22301396
references.citation: Semin Oncol. 2004 Dec;31(6 Suppl 13):16-35
references.pmid: 15717736
references.citation: Clin Pharmacokinet. 2006;45(9):871-903
references.pmid: 16928151
references.citation: Curr Drug Targets. 2000 Jul;1(1):85-99
references.pmid: 11475537
references.citation: J Microencapsul. 2013;30(1):49-54
references.pmid: 22676632
references.citation: Lancet. 2014 Dec 20;384(9961):2175-6
references.pmid: 25625382
references.citation: Biochem Pharmacol. 1995 May 17;49(10):1541-4
references.pmid: 7763297
references.citation: Ann N Y Acad Sci. 2006 Aug;1074:198-224
references.pmid: 17105918
references.citation: J Nanosci Nanotechnol. 2014 Jan;14(1):1007-17
references.pmid: 24730317
references.citation: Nanomedicine (Lond). 2013 Jan;8(1):123-43
references.pmid: 23256496
references.citation: Pharmacol Rev. 2004 Jun;56(2):185-229
references.pmid: 15169927
references.citation: Biochim Biophys Acta. 2014 Jan;1845(1):84-9
references.pmid: 24361676
references.citation: J Adv Res. 2015 Jan;6(1):45-62
references.pmid: 25685543
references.citation: Expert Opin Drug Deliv. 2013 Jul;10(7):1003-22
references.pmid: 23373728
references.citation: J Cereb Blood Flow Metab. 1997 Jul;17(7):713-31
references.pmid: 9270488
references.citation: Nat Rev Neurosci. 2011 Mar;12(3):169-82
references.pmid: 21331083
references.citation: Methods Enzymol. 2005;391:71-97
references.pmid: 15721375
references.citation: J Pharm Pharmacol. 2013 Feb;65(2):157-70
references.pmid: 23278683
references.citation: J Clin Neurosci. 2011 Nov;18(11):1444-8
references.pmid: 21813279
references.citation: J Control Release. 2007 Jan 22;117(1):51-8
references.pmid: 17150277
references.citation: Neurobiol Dis. 2010 Jan;37(1):48-57
references.pmid: 19664710
references.citation: Semin Oncol. 2004 Dec;31(6 Suppl 13):5-15
references.pmid: 15717735
references.citation: J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):481-6
references.pmid: 10480340
references.citation: Adv Drug Deliv Rev. 2010 Feb 17;62(2):192-202
references.pmid: 20005272
references.citation: Neuro Oncol. 2004 Jan;6(1):38-43
references.pmid: 14769139
references.citation: Semin Oncol. 1992 Dec;19(6):670-86
references.pmid: 1462166
references.citation: Expert Opin Drug Deliv. 2009 Oct;6(10):1017-32
references.pmid: 19732031
references.citation: Adv Drug Deliv Rev. 2014 May;71:2-14
references.pmid: 23981489
references.citation: Expert Rev Clin Pharmacol. 2012 Mar;5(2):173-86
references.pmid: 22390560
references.citation: Nat Rev Cancer. 2002 Jan;2(1):48-58
references.pmid: 11902585
references.citation: Biomaterials. 2015 Jan;37:425-35
references.pmid: 25453970
references.citation: Biochem Pharmacol. 2004 Jan 15;67(2):269-76
references.pmid: 14698039
references.citation: J Control Release. 2012 Jun 10;160(2):117-34
references.pmid: 22484195
references.citation: Nano Today. 2013 Jun 1;8(3):313-331
references.pmid: 23888183
references.citation: Anticancer Res. 2000 Mar-Apr;20(2B):1061-7
references.pmid: 10810398
references.citation: Biomacromolecules. 2010 Oct 11;11(10 ):2576-82
references.pmid: 20722436
references.citation: J Control Release. 2009 Jan 5;133(1):4-10
references.pmid: 18840484
references.citation: Mol Pharm. 2011 Jun 6;8(3):683-700
references.pmid: 21491921
references.citation: Adv Drug Deliv Rev. 2007 Jul 10;59(6):454-77
references.pmid: 17570559
references.citation: Pharm Res. 2010 Jan;27(1):200-8
references.pmid: 19894105
references.citation: Biochemistry. 1990 Mar 13;29(10):2538-49
references.pmid: 2334681